high-risk, bcg-unresponsive nmibc beyond rc: intravesical and systemic therapies
Published 7 months ago • 177 plays • Length 3:04Download video MP4
Download video MP3
Similar videos
-
9:32
what is the optimal therapy for bcg unresponsive high-risk nmibc:
-
2:01
keynote-057 cohort b: pembrolizumab for bcg-unresponsive, high-risk nmibc
-
19:31
adaptive immune resistance to intravesical bcg in nmibc: bcg-unresponsive clinical trials
-
2:04
why do bcg-unresponsive patients with nmibc refuse radical cystectomy?
-
26:18
controversies in non-muscle invasive bladder cancer (nmibc): guidelines and beyond 2023
-
51:36
treatment of high risk nmibc in era of bcg shortage - empire urology lecture series
-
4:12
systemic versus intravesical therapy for nmibc
-
29:46
introduction to adstiladrin | gene therapy for bcg unresponsive nmibc
-
0:49
current standards in bcg-unresponsive carcinoma in-situ and papillary nmibc
-
1:39:37
management of nmibc: practical solutions for common problems
-
1:08:14
urowebinar: bcg unresponsive disease how this definition impact your treatment decision making
-
3:16
keynote-057 update: pembrolizumab for high-risk nmibc patients
-
21:04
bcg unresponsive non-muscle invasive bladder cancer
-
1:00:50
bcg and beyond in non muscle-invasive bladder cancer
-
1:12
scott tagawa, md, on the study investigating nadofaragene firadenovec in bcg unresponsive nmibc
-
15:34
conversations in high-risk non-muscle invasive bladder cancer
-
59:53
ivumed vvp: recurrent nmibc and bcg unresponsive disease
-
0:27
cretostimogene plus pembrolizumab for bcg-unresponsive nmibc with cis #bladdercancer #cancer #news